Sign up
Pharma Capital

Q1 'very much a building quarter' for VolitionRx with growing cash reserves

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEMKTS:VNRX), discusses with Proactive Investors their Q1 2018 earnings.

The company reported a slower first quarter cash burn rate while growing cash reserves.

For the period ended March 31, it increased its cash and equivalents to US$14.3mln, compared to US$10.1mln in the previous quarter.

This week Volition entered into a sales and distribution partnership with Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology.


View full VNRX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.